NDLTD logo NDLTD Union Catalog and Global ETD Search

Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 25 for “"Androgen Deprivation Therapy (ADT)"”.

  1. Exercise and nutrition induced weight loss for prostate cancer patients

    Wilson, Rebekah LouiseEdith Cowan University, Research Online, Perth, Western Australia2020

    … examining prostate cancer patients receiving androgen deprivation therapy (ADT) and how exercise and nutrition interventions can be used to induce fat loss, while preserving or improving lean mass. Study 1 (Chapter 4) is an examination of the efficacy of a weight loss program in altering body …

    edithcowan Repository record

  2. Androgen Receptor and Prostate Cancer Cell Heterogeneity

    Deng, Qu, <p>orcid.org/0000-0003-0030-2511</p>2019

    <p>Androgen receptor (AR) plays an important role in prostate cancer (PCa) development and has been the main therapeutic target in advanced PCa. AR expression is heterogeneous in both primary PCa and castration resistant prostate cancer (CRPC). However, the functional significance of AR …

    uthsc Repository record

  3. CaV1.3 Ion channel expression and hormone therapy in prostate cancer

    McKerr, NiamhQueen's University Belfast2021

    … localised PCa is commonly treated with radiotherapy or surgery where recurrent tumours are treated with hormone therapy, such as androgen-deprivation therapy (ADT) and/or androgen receptor (AR) antagonists, e.g. Enzalutamide (ENZ). Castrate-resistant disease, where tumours become resistant to …

    qu-belfast Repository record

  4. A randomised controlled trial of a diet and physical activity intervention in prostate cancer patients and related studies.

    O'Neill, Roisin FrancesQueen's University Belfast2013

    The utilisation of Androgen Deprivation Therapy (ADT) in prostate cancer patients is associated with a number of adverse side effects including: changes in body composition; an increase in fat mass and a decrease in muscle mass, increased fatigue and a reduced Quality of Life (QoL). Existing …

    qu-belfast Repository record

  5. The role of BET proteins in castration-resistant prostate cancer dissemination

    Shafran, Jordan Seth2020

    … primary or acquired resistance to conventional androgen-deprivation therapy (ADT) and accumulated resistance mechanisms to evade androgen receptor (AR) suppression. Whereas the canonical androgen/AR signaling axis maintains prostate cell growth, differentiation and survival, in prostate cancer …

    bu Repository record

  6. Evaluating the role of a 99mTc-HYNIC-PSMA SPECT scan following a negative bone scan in men with prostate cancer: a single-centre, retrospective cohort study

    Oppel, CleveDivision of General Surgery2023

    … both scans negative included external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) (n = 47), and radical prostatectomy with or without lymph node (LN) dissection (n = 4). A limiting factor was that not every patient underwent conventional cross-sectional imaging of the pelvis …

    cape-town Repository record

  7. Nutritional factors and lifestyle in prostate cancer patients

    Haseen, FarhanaQueen's University Belfast2011

    … specifically for those who are treated with androgen deprivation therapy (ADT). To achieve these aims this thesis has documented the findings of the following studies investigating nutritional and life-style behaviours in prostate cancer patients. <br/>1) Using the cross-sectional …

    kings Repository record

  8. DOES STRENGTH TRAINING IMPROVE MUSCULOSKELETAL HEALTH AND BODY COMPOSITION IN BLACK MEN WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY?

    Hanson, Erik2011

    … previous studies. PCa is commonly treated using androgen deprivation therapy (ADT). However, ADT induces numerous adverse side effects, including loss of muscle mass, strength, power, and physical function with concomitant increases in fat mass, fatigue, and bone fractures. Because strength …

    maryland Repository record

  9. Novel Mechanisms of Β-Adrenergic Signaling In Prostate Cancer Progression

    Hulsurkar, Mohit2017

    … er/detailedguide/prostate-cancer-key-statistics). Androgen deprivation therapy (ADT) is the standard treatment for early stage prostate cancer. But most patients relapse with aggressive variants of prostate cancer, with survival time between 1-3 years. In order to develop cure for such aggressive …

    uthsc Repository record

  10. Phage Display Library Screening For Psa-/Lo Prostate Cancer Cell-Binding Peptides

    Moore, John R.2015

    … cells responsible for driving PCa and mediating therapy resistance. My master thesis research employs a phage display library screening technology aiming to identify peptides that preferentially home in to undifferentiated PCa cells, which our lab has previously demonstrated to be intrinsically …

    uthsc Repository record

  11. Targeting the Tumor Stroma Using a Monoclonal Antibody Platform Technology

    Hintz, Hallie2021

    … American men. Men who fail standard-of-care androgen deprivation therapy (ADT) and progress to metastatic castration resistant prostate cancer (mCRPC) are left with few therapeutic options. Current second line therapies only provide a small survival benefit and there is a critical unmet need …

    umn Repository record

  12. Self-reported Exercise and Risk of Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

    Mennen-Winchell, Lori J.

    … stimulated to grow in response to testosterone. Androgen deprivation therapy (ADT) leads to chemical castration and suppression of prostate cancer cell production. Testosterone levels less then 300ng/ml decreases bone mineral density and could result in osteoporosis. Studies have shown that …

    loma-linda Repository record

  13. Exercise as medicine : reversing treatment toxicities in prostate cancer patients

    Wall, Bradley A.Edith Cowan University, Research Online, Perth, Western Australia2013

    … cancer after skin cancer in Australian males, is androgen deprivation therapy (ADT). However, ADT is associated with an array of adverse effects including reduced bone and lean mass, loss of muscle strength, negative change in lipid profile, and increased risk of cardiovascular disease (CVD) as …

    edithcowan Repository record

  14. Investigation of the role of Col4a1 and Itga11 in enzalutamide resistance of prostate cancer cells

    Ciszek, AleksandraThe University of Edinburgh2022

    … cancer in males in the Western World. Androgen Deprivation Therapy (ADT) is initially effective in patients with localized prostate cancer (PCa), but eventually, cancer cells develop resistance to therapy and progress into Castration-Resistant Prostate Cancer (CRPC). CRPC is very likely …

    edinburgh Repository record

  15. Role of the extracellular matrix-integrin interaction in enzalutamide resistance of bone metastatic castration-resistant prostate cancer

    Zhang, ChengbinThe University of Edinburgh2024

    … of all metastasis incidence. Its resistance to androgen-deprivation therapy (ADT). Enzalutamide (Enz) is a second-generation androgen-receptor (AR) antagonist, developed to treat bone mCRPC by blocking the androgen signalling pathway. However, the emergence of resistance to Enz significantly …

    edinburgh Repository record

  16. The analysis of dynamic contrast-enhanced magnetic resonance imaging data: treatment effects, sampling rates and repeatability

    Gill, Andrew BrianUniversity of Cambridge2013

    … that the effects of platinum-based chemotherapy and androgen deprivation therapy (ADT) respectively can be correlated with changes in standard DCE-MRI parameters (Ktrans, ve and vp). The results show that ADT is reflected by decreasing tumour perfusion and vascularity (Ktrans and vp) …

    cambridge Repository record

  17. IDENTIFICATION OF NCAM1 AS A NOVEL PROGNOSTIC PROSTATE CANCER STEM CELL BIOMARKER

    CASTIGLIONI, ANDREAUniversità degli Studi di Milano2022

    … for tumorigenesis, disease progression and therapy failure. Their identification and characterization are mandatory for understanding the intricate intratumoral heterogeneity (spatial and molecular) of PCa and for developing relevant clinical tools to effectively manage patients and tailor …

    milano Repository record

  18. Regulation of Systemic and Cellular Metabolism In Prostate Cancer By Camkk2 and Elucidation of Atgl’S Role In Disease Progression

    Awad, Dominik, <p><strong>0000-0002-7386-2061</strong></p>2025

    <p>The androgen receptor (AR) is the major driver of prostate cancer; hence, men with progressing disease are treated with androgen deprivation therapy (ADT). However, the majority of patients will relapse within 2-3 years due to multiple AR reactivation mechanisms. Thus, AR and the processes …

    uthsc Repository record

  19. Radiobiological mechanisms and novel imaging biomarkers in metastatic prostate cancer treated with radium-223

    Alshehri, Ali Hamad DQueen's University Belfast2021

    … cancer patients who initially respond to Androgen deprivation therapy (ADT), will eventually progress to castration-resistant prostate cancer (CRPC). Bone metastases are an extremely common disease state, present in 90% of patients with metastatic CRPC (mCRPC). The use of alpha …

    qu-belfast Repository record

  20. Investigating a novel combination treatment of androgen deprivation therapy, pelvic external beam radiotherapy and radium-223 dichloride in the management of hormone sensitive prostate cancer metastatic to bone

    Turner, PhilipQueen's University Belfast2020

    … for whichthe mainstay of treatment consists of androgen deprivation therapy (ADT).Recently a number of treatments added to ADT have been shown to extend survivalin these patients including docetaxel and abiraterone as well as external beamradiotherapy (EBRT) to prostate (in low volume disease). …

    qu-belfast Repository record

Page 1 of 2